BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

The most recent Phase III data from a heart failure candidate may have been underwhelming, but a look at the broader pipeline suggests the long period of drought in innovation could soon give way to...
BioCentury | Jun 23, 2020
Distillery Therapeutics

Overexpressing OXCT1-AS1, a long non-coding RNA, for heart attacks

DISEASE CATEGORY: Cardiovascular INDICATION: Myocardial infarction (MI) Promoting the expression of the long non-coding RNA OXCT1-AS1 could treat MI by directly reducing cardiomyocyte apoptosis and indirectly inducing endothelial cell proliferation. In human cardiomyocytes, OXCT1-AS1 overexpression...
BioCentury | Apr 8, 2020

Suzhou Ribo raises $66.3M for nucleic acid therapies

Four months after closing a RMB203 million ($28.8 million) series C round, Suzhou Ribo Life Science Co. Ltd. has raised an additional RMB470 million in a series C2 round to advance its RNAi and antisense...
BioCentury | Feb 6, 2020
Product Development

Early signs CAR NKs could compete with CAR Ts in heme cancers

Early clinical data from CAR NK cells have started to roll in, and hint the modality could compete with CAR T cells on efficacy. Built into CAR NK cells are the benefits of off-the-shelf manufacturing...
BioCentury | Jan 28, 2020
Company News

Quenching the flames of inflammatory cell death

Emerging from stealth Monday with a $50 million A round, Quench Bio is targeting the nexus of inflammatory cell death. RA Capital led the round with participation from new investor AbbVie Ventures. Atlas Venture and...
BioCentury | Oct 8, 2019

Inhibiting caspase-mediated pyroptosis for graft-versus-host disease

DISEASE CATEGORY: Transplant INDICATION: Graft-versus-host disease (GvHD) Inhibiting CASP4 or CASP5, the human homologs of murine pyroptosis activator CASP11, or the downstream mediators GSDMD and IL-1α could prevent GvHD in leukemia patients undergoing allogeneic hematopoietic...
BioCentury | Sep 20, 2019
Emerging Company Profile

Divide & Conquer: short-circuiting tumor lines of communication

Divide & Conquer aims to capitalize on new tumor biology that would prevent cancer cells from sharing resistance mechanisms and resensitize the tumor to chemo- and radiotherapy. Medicxi’s David Grainger founded the company in 2018...
BioCentury | Aug 29, 2019
Distillery Techniques

The E3 ligase CHIP as an Alzheimer's disease biomarker

...tau (microtubule-associated protein tau; MAPT; FTDP-17) cleavage product -- tau D421-- and activated caspase-6 (CASP6; MCH2...
...previously been associated with AD pathology. In vitro , CHIP bound tau D421 and activated CASP6...
...Jason E. Gestwicki, same affiliation as above e-mail: Inhua Muijrers-Chen University of California San Francisco Caspase-6 (CASP6) (MCH2) Microtubule-associated...
BioCentury | Aug 16, 2019
Targets & Mechanisms

Biotechs explore the next generation of inflammasome targets, with caution

As the NLRP3 field gains momentum, drawing VC and pharma interest for the role the target plays in diseases ranging from NASH to neurodegeneration, biotechs are beginning to eye the next crop of inflammasome targets....
BioCentury | Jun 26, 2019
Company News

June 25 Company Quick Takes: Conatus restructuring; plus Almirall-Dermira, Acer, Glenmark and more

Conatus cuts headcount by 40% to extend runway Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) said it will lay off 40% of its staff and suspend development of caspase 1 inhibitor CTS-2090 in a bid to extend its...
Items per page:
1 - 10 of 463